Precision Biosensor

Precision Biosensor EBIT Margin

The EBIT Margin (Operating Margin) of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is -27.01 %. In the previous year, EBIT Margin (Operating Margin) was -28.55 % — a change of -5.39% (higher).

EBIT Margin

-27.01 %

YoY

-5.39%

Last updated:

EBIT Margin (Operating Margin) of Precision Biosensor is 2025 -27.01 % . EBIT Margin (Operating Margin) of Precision Biosensor was 2024 -28.55 % . It decreases by -5.39% higher compared to the previous year.

Precision Biosensor's operating (EBIT) margin stands at -27.0%, down from -25.1% several years earlier.

The Precision Biosensor EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-61.89 KRW
Jan 1, 2019
-42.49 KRW
Jan 1, 2020
-16.86 KRW
Jan 1, 2021
-25.08 KRW
Jan 1, 2022
-31.16 KRW
Jan 1, 2023
-23.03 KRW
Jan 1, 2024
-28.55 KRW
Jan 1, 2025
-27.01 KRW
The Precision Biosensor EBIT Margin history
YEAREBIT MarginYoY
-27.01 %-5.39%
-28.55 %+23.96%
-23.03 %-26.10%
-31.16 %+24.26%
-25.08 %+48.78%
-16.86 %-60.33%
-42.49 %-31.34%
-61.89 %+23.61%
-50.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

EBIT Margin (Operating Margin) of Precision Biosensor is -27.01 % in 2025.

EBIT Margin (Operating Margin) of Precision Biosensor changed from -28.55 % to -27.01 %, representing a -5.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Precision Biosensor with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Precision Biosensor

All Key Metrics — Precision Biosensor